	US 11,717,653 B2
	Drug-coated angioplasty balloons
Simone D'Onofrio, Coccaglio (IT); Massimo Morero, Bricherasio (IT); Federica Bellucci, Alessandria (IT); Bradley E. Steele, Plymouth, MN (US); and Diane M. Haen, St. Louis Park, MN (US)
Assigned to Medtronic Vascular, Inc., Santa Rosa, CA (US)
Filed by Medtronic Vascular, Inc., Santa Rosa, CA (US)
Filed on May 29, 2020, as Appl. No. 16/887,307.
Prior Publication US 2021/0370028 A1, Dec. 2, 2021
Int. Cl. A61M 25/10 (2013.01); A61K 31/436 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01)

CPC A61M 25/104 (2013.01) [A61K 31/436 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61M 25/1029 (2013.01); A61L 2300/204 (2013.01); A61L 2300/21 (2013.01); A61L 2300/216 (2013.01); A61L 2300/416 (2013.01); A61L 2300/63 (2013.01); A61L 2300/802 (2013.01); A61L 2420/02 (2013.01); A61M 2025/105 (2013.01); A61M 2025/1031 (2013.01)]

20 Claims

1. An angioplasty balloon comprising a surface having disposed thereon a single-layer coating comprising at least one limus drug, a portion of which is in the form of crystals, wherein no more than 30 wt-% of the total limus drug is in the form of crystals, and further wherein the angioplasty balloon is in a deployable configuration.